|
| Control | Case |
| |
|
| Sulfonylureas |
| Chlorpropamide, third |
| None used (0 mg) | 6217 (99.89%) | 1554 (99.87%) |
| Low concentration (≤third quartile) | 5 (0.08%) | 1 (0.06%) |
| High concentration (>third quartile) | 2 (0.03%) | 1 (0.06%) |
| Glibenclamide, third |
| None used (0 mg) | 4251 (68.3%) | 988 (63.5%) |
| Low concentration (≤third quartile) | 1387 (22.28%) | 422 (27.12%) |
| High concentration (>third quartile) | 586 (9.42%) | 146 (9.38%) |
| Glimepiride, third |
| None used (0 mg) | 4033 (64.8%) | 986 (63.37%) |
| Low concentration (≤third quartile) | 1476 (23.71%) | 393 (25.26%) |
| High concentration (>third quartile) | 715 (11.49%) | 177 (11.38%) |
| Gliclazide, third |
| None used (0 mg) | 4039 (64.89%) | 961 (61.76%) |
| Low concentration (≤third quartile) | 1530 (24.58%) | 436 (28.02%) |
| High concentration (>third quartile) | 655 (10.52%) | 159 (10.22%) |
| Tolbutamide, third |
| None used (0 mg) | 6224 (100%) | 1556 (100%) |
| Low concentration (≤third quartile) | 0 (0%) | 0 (0%) |
| High concentration (>third quartile) | 0 (0%) | 0(0%) |
| Tolazamide, third |
| None used (0 mg) | 6180 (99.29%) | 1546 (99.36%) |
| Low concentration (≤third quartile) | 30 (0.48%) | 8 (0.51%) |
| High concentration (>third quartile) | 14 (0.22%) | 2 (0.13%) |
| Biguanides |
| Metformin, third |
| None used | 2414 (38.79%) | 541 (34.77%) |
| Low concentration (≤third quartile) | 2717 (43.65%) | 757 (48.65%) |
| High concentration (>third quartile) | 1093 (17.56%) | 258 (16.58%) |
| Buformin, third |
| None used | 6211 (99.79%) | 1550 (99.61%) |
| Low concentration (≤third quartile) | 9 (0.14%) | 4 (0.26%) |
| High concentration (>third quartile) | 4 (0.06%) | 2 (0.13%) |
| Meglitinides |
| Repaglinide, third |
| None used (0 mg) | 5434 (87.31%) | 1304 (83.8%) |
| Low concentration (≤third quartile) | 484 (7.78%) | 169 (10.86%) |
| High concentration (>third quartile) | 306 (4.92%) | 83 (5.33%) |
| Nateglinide, third |
| None used (0 mg) | 6062 (97.4%) | 1494 (96.02%) |
| Low concentration (≤third quartile) | 105 (1.69%) | 35 (2.25%) |
| High concentration (>third quartile) | 57 (0.92%) | 27 (1.74%) |
| α-Glucosidase inhibitor |
| Acarbose, third |
| None used (0 mg) | 4909 (78.87%) | 1233 (79.24%) |
| Low concentration (≤third quartile) | 855 (13.74%) | 215 (13.82%) |
| High concentration (>third quartile) | 460 (7.39%) | 108 (6.94%) |
| Miglitol, third |
| None used (0 mg) | 6181 (99.31%) | 1542 (99.1%) |
| Low concentration (≤third quartile) | 18 (0.29%) | 9 (0.58%) |
| High concentration (>third quartile) | 25 (0.4%) | 5 (0.32%) |
| Thiazolidinediones |
| Rosiglitazone, third |
| None used (0 mg) | 5355 (86.04%) | 1324 (85.09%) |
| Low concentration (≤third quartile) | 599 (9.62%) | 175 (11.25%) |
| High concentration (>third quartile) | 270 (4.34%) | 57 (3.66%) |
| Pioglitazone, third |
| None used (0 mg) | 5391 (86.62%) | 1348 (86.63%) |
| Low concentration (≤third quartile) | 504 (8.1%) | 129 (8.29%) |
| High concentration (>third quartile) | 329 (5.29%) | 79 (5.08%) |
|
